13F Holdings
中文EN

SNDX Syndax Pharmaceuticals Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%

Returns

ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x

Leverage & solvency

Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$172.35M$23.68M$0$0$139.71M
R&D expense$258.78M$241.65M$163.03M$118.50M$88.25M
SG&A expense$179.68M$120.88M$66.92M$33.26M$25.24M
Operating income-$273.08M-$339.67M-$229.95M-$151.76M$26.22M
Interest expense$6,000-$1,000$208,000$3.14M$1.90M
Income tax$433,000———$0
Net income-$285.42M-$318.76M-$209.36M-$149.34M$24.93M
EBITDA-$267.08M-$331.67M-$217.95M-$118.76M$69.22M
EPS (basic)-3.29-3.72-2.98-2.460.48
EPS (diluted)-3.29-3.72-2.98-2.460.46
Weighted avg. shares (diluted)86.63M85.62M70.37M60.76M53.62M
Balance sheet
Cash & equivalents$134.93M$154.08M$295.39M$74.36M$221.97M
Short-term investments$259.14M$418.80M$275.30M$401.45M$217.97M
Receivables$38.00M$7.60M$0——
Inventory$32.75M$366,000$0——
Current assets$528.08M$603.06M$580.88M$489.79M$448.40M
PP&E, net$181,000$0$8,000$20,000$278,000
Total assets$529.71M$724.82M$612.88M$497.24M$449.66M
Current liabilities$120.12M$103.55M$58.10M$29.07M$20.68M
Short-term debt$343.91M$343.68M$0——
Total liabilities$465.08M$436.69M$58.68M$29.79M$41.29M
Shareholders' equity$64.63M$288.12M$554.20M$467.45M$408.37M
Shares outstanding87.41M85.69M84.83M68.11M54.98M
Cash flow statement
Operating cash flow-$322.98M-$274.90M-$160.60M-$133.68M$29.13M
Capital expenditure$187,000$0$0$0$129,000
Free cash flow-$323.17M-$274.90M-$160.60M-$133.68M$29.00M
Investing cash flow$290.04M-$219.78M$117.61M-$186.19M-$40.87M
Financing cash flow$13.68M$353.37M$264.13M$172.25M$118.46M
Depreciation & amortization$6.00M$8.00M$12.00M$33.00M$43.00M
Stock-based compensation$47.50M$43.03M$30.95M$16.02M$13.32M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.